The tumor microenvironment (TME) is the complex ecosystem of cells, molecules, and physical conditions that surrounds and supports a tumor. It includes immune cells, connective tissue cells, blood vessels, signaling molecules, and a structural scaffold called the extracellular matrix. Far from being a passive bystander, this environment actively helps tumors grow, evade the immune system, and spread to other parts of the body. Understanding the TME has become central to modern cancer treatment, especially immunotherapy.
The Cells That Make Up the TME
A tumor is not just a mass of cancer cells. It is a mixture of many cell types, each playing a role in how the cancer behaves. The primary cellular residents of the TME include T cells, B cells, tumor-associated macrophages, neutrophils, and cancer-associated fibroblasts (CAFs).
T cells and B cells are immune cells that, in a healthy body, would recognize and destroy abnormal cells. Inside the TME, however, tumors often find ways to suppress or redirect these cells so they become less effective or even helpful to the cancer. Tumor-associated macrophages are immune cells that normally clean up damaged tissue, but within the TME they frequently switch to a pro-tumor mode, releasing signals that promote blood vessel growth and suppress anti-tumor immunity.
Cancer-associated fibroblasts are among the most influential non-cancer cells in the TME. In normal tissue, fibroblasts maintain structural integrity. Once “recruited” by a tumor, they produce far more structural proteins than normal fibroblasts and secrete growth signals that feed the cancer. They also help build the dense, stiff tissue that surrounds many solid tumors, which can physically block immune cells and drugs from reaching cancer cells.
Blood vessel cells (endothelial cells) and lymphatic vessel cells round out the picture. Tumors stimulate the growth of new, often abnormal blood vessels to secure their own nutrient supply, a process called angiogenesis. When tumors reduce the activity of a key growth signal that drives this process, the resulting tumors show significantly less blood vessel density and slower growth.
The Structural Scaffold: Extracellular Matrix
Between all these cells sits the extracellular matrix (ECM), a meshwork of proteins and sugar-coated molecules that gives tissue its structure. In the TME, the ECM is composed of collagens, glycoproteins like fibronectin and laminins, proteoglycans, and complex sugars. Cancer-associated fibroblasts are the main producers of this material, and they generate it in excess compared to normal tissue.
This isn’t just structural filler. In cancer, the collagen network gets reorganized in ways that actively help tumor cells move through tissue. Collagen and elastin fibers are reoriented and chemically cross-linked by specific enzymes, creating larger, more rigid fibers that essentially lay down tracks for migrating cancer cells. Cancer cells, fibroblasts, and macrophages all contribute to this remodeling, especially under low-oxygen conditions.
Proteoglycans, another major ECM component, also change in cancer. Their expression and location shift in the TME, influencing how cancer cells invade surrounding tissue and spread to distant sites. In lung cancer, for example, the balance between certain proteoglycans and sulfated sugar chains in the matrix has been linked to patient survival, suggesting these molecules could serve as biomarkers.
Low Oxygen and Acidic Conditions
The interior of a solid tumor is a harsh place. Because tumors outgrow their blood supply, oxygen levels drop dramatically. Normal tissue typically has an oxygen tension of 40 to 60 mmHg. Tumor tissue is generally classified as oxygen-deprived (hypoxic) when that number falls below 10 mmHg. This oxygen shortage isn’t just a side effect; it drives some of the most dangerous behaviors in cancer.
Hypoxia triggers a cellular transition where cancer cells lose their tendency to stay in place and gain the ability to move. This process, known as epithelial-mesenchymal transition (EMT), plays a role in invasion, metastasis, treatment resistance, and the development of cancer stem-like cells. In other words, low oxygen pushes cancer cells toward a more aggressive state.
The TME is also more acidic than normal tissue. Healthy tissue maintains a pH around 7.4, while tumor tissue drops to roughly 6.8. This acidity comes largely from lactate, a byproduct of the way cancer cells process energy. Lactate concentrations in the TME reach 10 to 30 millimolar, compared to just 1.5 to 3.0 millimolar under normal conditions. The acidic environment further suppresses immune cell function and can make certain therapies less effective.
How Tumor Cells Communicate With Their Surroundings
The TME runs on chemical signals. Tumors and the cells around them release a complex mix of cytokines and chemokines, small proteins that act as messages between cells. Some of these signals recruit immune-suppressing cells to the tumor site. For instance, signaling molecules like CCL3, CCL4, and CCL5 draw in myeloid-derived suppressor cells, a type of immune cell that actively blocks anti-tumor responses. Elevated CCL5 levels isolated in breast and cervical cancers have been linked to more advanced disease stages, relapse, and metastasis.
Once suppressive immune cells arrive, they release their own cocktail of molecules, including nitric oxide, arginase, and immunosuppressive cytokines like IL-10 and TGF-β. These dampen the activity of T cells that might otherwise attack the tumor. Meanwhile, other signals such as TNF-α, IL-1, and IL-6 promote tumor growth by activating pathways involved in cell survival, proliferation, and spread. The net effect is a signaling network that tilts the immune system in the tumor’s favor.
Why the TME Matters for Treatment
The TME is the reason immunotherapy works brilliantly for some patients and fails completely for others. Immune checkpoint inhibitors, the most widely used class of immunotherapy, work by releasing the brakes that tumors place on T cells. But if the TME has already created an environment where T cells are exhausted, excluded, or heavily suppressed, removing the brakes alone may not be enough.
Research using single-cell sequencing across 16 cancer types and more than 300,000 individual cell profiles has revealed that T cells inside tumors exist in a range of states. One notable finding is a stress response in tumor-infiltrating T cells, characterized by elevated activity of heat shock genes, that appears particularly prominent in patients who don’t respond to checkpoint therapy. This stress state may represent a mechanism the TME uses to neutralize T cells even after immunotherapy.
Scientists are also paying attention to structures called tertiary lymphoid structures, which are clusters of immune cells within or near tumors that resemble miniature lymph nodes. These clusters are rich in B cells and antibody-producing cells, and their presence has been associated with better responses to immunotherapy across multiple cancer types.
Computational tools now combine tumor-specific features (like mutation burden and the types of molecules displayed on cancer cell surfaces) with TME features (like immune cell positions, cell-to-cell communication networks, and the diversity of immune receptors present) to predict which patients will benefit from a given treatment. Artificial intelligence is increasingly used to analyze this data.
Therapeutic Approaches Targeting the TME
Because the TME plays such a large role in cancer progression and treatment resistance, an entire branch of oncology research is focused on targeting it directly. Rather than aiming only at cancer cells, these strategies try to reshape the environment around them.
CAR-T cell therapy, which engineers a patient’s own immune cells to recognize and attack cancer, is being refined to better survive the hostile conditions of the TME. Natural killer cell therapies and dendritic cell-based approaches are also being developed to boost anti-tumor immunity from different angles. Another active area of research targets cancer-associated fibroblasts, aiming to disrupt the structural and chemical support they provide to tumors. Combining these TME-targeting strategies with existing immunotherapies is a major focus of ongoing clinical trials.